Author/Editor		Vrtovec, Matjaž
Title		Debel sladkorni bolnik tipa 2
Type		članek
Source		In: Pfeifer M, Rotovnik-Kozjek N, editors. Debelost. 2. strokovno srečanje Slovenskega združenja za klinično prehrano; 2006 sep 8; Ljubljana. Ljubljana: Združenje za klinično prehrano,
Publication year		2006
Volume		str. 45-52
Language		slo
Abstract		The prevalence of type 2 diabetes is showing a rapid progression worldwide, a phenomenon largely resulting from the epidemic proportions reached by obesity in various populations of the world. Body fat distribution, especially intra-abdominal adipose tissue accumulation, has been found to be a key correlate of a cluster of diabetogenic, atherogenic, prothrombotic and inflammatory metabolic abnormalities increasing the risk of type 2 diabetes and cardiovascular disease. Lifestyle modification programs have shown the benefits on cardiometabolic risk variables of a moderate weight loss as it has been found to be associated with a substantial loss of intra-abdominal fat in viscerally obese patients. Currently, thiazolidinediones and tibrates, new-generation peroxisome proliferator-activated receptor (PPAR) agonists, incretin mimetics, dipeptidyl peptidase IV inhibitors, protein tyrosine phosphatase 1B inhibitors, and endocannabinoid receptor blocking agents are cited as potential emerging therapies for multiple clustering cardiometabolic risk factors.
Descriptors		DIABETES MELLITUS, NON-INSULIN-DEPENDENT OBESITY DIET, REDUCING